Published in J Pathol on October 01, 2009
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell (2011) 3.47
Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS One (2013) 1.10
Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin Cancer Res (2013) 0.98
Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol (2014) 0.95
Bmi1 is required for regeneration of the exocrine pancreas in mice. Gastroenterology (2012) 0.88
Dual Roles of RNF2 in Melanoma Progression. Cancer Discov (2015) 0.86
Pathway Regulation of p63, a Director of Epithelial Cell Fate. Front Endocrinol (Lausanne) (2015) 0.85
The Polycomb group protein RING1B is overexpressed in ductal breast carcinoma and is required to sustain FAK steady state levels in breast cancer epithelial cells. Oncotarget (2014) 0.84
H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma. Oncotarget (2014) 0.84
New insights into pancreatic cancer stem cells. World J Stem Cells (2015) 0.84
Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. Cancer Res (2014) 0.82
The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol Cancer (2013) 0.82
Polycomb and the emerging epigenetics of pancreatic cancer. J Gastrointest Cancer (2011) 0.79
Bmi1 is required for the initiation of pancreatic cancer through an Ink4a-independent mechanism. Carcinogenesis (2015) 0.79
Polycomb repressor complex 1 promotes gene silencing through H2AK119 mono-ubiquitination in acinar-to-ductal metaplasia and pancreatic cancer cells. Oncotarget (2016) 0.78
MiR-204 silencing in intraepithelial to invasive cutaneous squamous cell carcinoma progression. Mol Cancer (2016) 0.78
RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein. Oncotarget (2016) 0.76
Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine. Oncotarget (2016) 0.75
Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language. Yale J Biol Med (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell (2007) 8.47
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Mammalian cyclin-dependent kinases. Trends Biochem Sci (2005) 5.54
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet (2005) 5.01
The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell (2011) 4.79
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet (2003) 4.74
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell (2004) 4.39
Cdk1 is sufficient to drive the mammalian cell cycle. Nature (2007) 4.26
A pericyte origin of spinal cord scar tissue. Science (2011) 4.12
A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell (2010) 3.97
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta (2002) 3.77
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet (2007) 3.30
Isolation and in vitro expansion of human colonic stem cells. Nat Med (2011) 3.20
Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell (2012) 2.94
Three-year outcomes for Medicare beneficiaries who survive intensive care. JAMA (2010) 2.87
New paradigm for macromolecular crystallography experiments at SSRL: automated crystal screening and remote data collection. Acta Crystallogr D Biol Crystallogr (2008) 2.79
Regulation of pancreatic beta-cell mass. Physiol Rev (2005) 2.66
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.59
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Cell cycle kinases in cancer. Curr Opin Genet Dev (2007) 2.46
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. Nat Genet (2013) 2.44
p53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle (2011) 2.42
EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet (2007) 2.33
Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell. J Invest Dermatol (2013) 2.31
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell (2011) 2.28
Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol (2013) 2.26
Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development (2004) 2.21
Relationship Between ICU Length of Stay and Long-Term Mortality for Elderly ICU Survivors. Crit Care Med (2016) 2.03
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet (2012) 2.03
Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol (2009) 1.99
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
Mosaic uniparental disomies and aneuploidies as large structural variants of the human genome. Am J Hum Genet (2010) 1.97
Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol (2007) 1.96
CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci (2007) 1.95
Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A (2006) 1.93
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev (2006) 1.84
Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol (2006) 1.83
Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. Environ Health Perspect (2010) 1.81
P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol (2005) 1.79
Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol (2007) 1.78
What we have learned about pancreatic cancer from mouse models. Gastroenterology (2012) 1.78
Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell (2005) 1.78
Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools. Am J Epidemiol (2006) 1.73
Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet (2007) 1.68
Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res (2007) 1.68
Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J (2010) 1.66
Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery (2005) 1.64
Rapid progression of midventricular obstruction in adults with double-chambered right ventricle. J Thorac Cardiovasc Surg (2003) 1.64
Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene (2003) 1.62
Chromatin-bound IκBα regulates a subset of polycomb target genes in differentiation and cancer. Cancer Cell (2013) 1.61
Total fluid and water consumption and the joint effect of exposure to disinfection by-products on risk of bladder cancer. Environ Health Perspect (2007) 1.60
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res (2006) 1.57
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Poly(ADP-ribose) polymerase 1 is inhibited by a histone H2A variant, MacroH2A, and contributes to silencing of the inactive X chromosome. J Biol Chem (2007) 1.53
Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev (2007) 1.52
DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. Nat Struct Mol Biol (2010) 1.49
Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice. Hepatology (2013) 1.48
Use of Intensive Care Services for Medicare Beneficiaries Undergoing Major Surgical Procedures. Anesthesiology (2016) 1.47
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol (2011) 1.46
Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell (2011) 1.44
Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol (2005) 1.44
Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRas(G12V)-driven pancreatic tumourigenesis. Gut (2013) 1.43
Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev (2006) 1.43
Notch signaling as gatekeeper of rat acinar-to-beta-cell conversion in vitro. Gastroenterology (2009) 1.42
Cerebellar GABAergic progenitors adopt an external granule cell-like phenotype in the absence of Ptf1a transcription factor expression. Proc Natl Acad Sci U S A (2007) 1.41
Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Gut (2011) 1.41
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet (2012) 1.40
A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest (2008) 1.38
Key contribution of CPEB4-mediated translational control to cancer progression. Nat Med (2011) 1.37
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet (2011) 1.36
Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci U S A (2012) 1.36
Genetic variation in the base excision repair pathway and bladder cancer risk. Hum Genet (2007) 1.33
A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics (2011) 1.33
Exocrine cell transdifferentiation in dexamethasone-treated rat pancreas. Virchows Arch (2003) 1.33
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol (2013) 1.32
Cdk4 promotes adipogenesis through PPARgamma activation. Cell Metab (2005) 1.31
Diabetes and exocrine pancreatic insufficiency in E2F1/E2F2 double-mutant mice. J Clin Invest (2004) 1.29